DB Commodity Double Short ETN
Limited financial coverage for DEE.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
This index is designed to gauge the price fluctuations of futures agreements tied to various commodities such as crude oil, heating oil, corn, wheat, gold, and aluminum. Furthermore, a T-Bill Index component aims to simulate the earnings generated by regularly investing in 3-month U. S.
- IPO
- 2009
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on DEE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- 52W High
- $55.00
- 52W Low
- $55.00
- 50D MA
- $55.00
- 200D MA
- $55.00
- Beta
- -1.90
- RSI (14)
- 100
- Avg Volume
- 0
No earnings-call transcripts are available for DEE yet.
- Free Float
- 0.0%
- Shares Outstanding
- 1.86K
- Float Shares
- 0
of shares held by institutions
1 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Jane Street Holding, LLC | 26.23K | ▼ 1.64K |
| Ubs AG | 96 | ▲ 96 |
Our DEE coverage
Recent articles, reports, and earnings notes.
No research on DEE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DEE report →Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
gurufocus.com · Oct 5
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
gurufocus.com · Sep 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.